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Background: Frequent consumption of a diet high in fat and sucrose contributes to lifestyle-related diseases.
However, limited information is available regarding the short-term effects of such a diet on the onset of obesity-
associated metabolic abnormalities.
Methods: Male C57BL/6 J mice were divided into two groups and fed a standard chow diet (control group) or a
high fat–high sucrose diet containing 21% fat and 34% sucrose (HF–HS diet group) for 2 or 4 weeks.
Results: The HF–HS diet significantly induced body weight gain beginning at week 1 and similarly increased
mesenteric white adipose tissue weight and plasma insulin levels at weeks 2 and 4. Plasma resistin levels were
notably elevated after feeding with the HF–HS diet for 4 weeks. Measurement of hepatic triglycerides and Oil Red
O staining clearly indicated increased hepatic lipid accumulation in response to the HF–HS diet as early as 2 weeks.
Quantitative PCR analysis of liver and white adipose tissue indicated that, starting at week 2, the HF–HS diet
upregulated mRNA expression from genes involved in lipid metabolism and inflammation and downregulated
genes involved in insulin signalling. Although plasma cholesterol levels were also rapidly increased by the HF–HS
diet, no differences were found between the control and HF–HS diet–fed animals in the expression of key genes
involved in cholesterol biosynthesis.
Conclusions: Our study demonstrates that the rapid onset of hepatosteatosis, adipose tissue hypertrophy and
hyperinsulinemia by ingestion of a diet high in fat and sucrose may possibly be due to the rapid response of
lipogenic, insulin signalling and inflammatory genes.
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Being overweight or obese is one of the leading risks for
death worldwide. Increasing evidence has indicated that
obesity is linked to numerous comorbidity diseases such
as type 2 diabetes, hypertension, hypercholesterolaemia,
hypertriglyceridaemia, and non-alcoholic fatty liver dis-
ease [1-3]. It is estimated that 20–25% of the world’s
adult population has obesity-related metabolic syndrome,* Correspondence: yangzh@nissui.co.jp
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reproduction in any medium, provided the orand they are twice as likely to die and three times as
likely to have a heart attack or stroke compared with
people without the syndrome [4,5]. Besides an obeso-
genic environment and reduced energy expenditure dur-
ing work and leisure activities, one of the primary causes
of the current epidemic of obesity and related metabolic
disorders is related to the western-style diet, which
includes excessive intake of high-fat and high-sucrose
foods. Several studies have assessed the long-term (over
10 weeks ~ 2 years) effects of high-fat and/or high-
sucrose diets on metabolic risk factors [6-8]. On thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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short-term effects of a high fat–high sucrose (HF–HS)
diet on the onset of hepatosteatosis and changes in the
expression of genes involved in lipid and cholesterol me-
tabolism, insulin signalling, and inflammation in liver
and white adipose tissue (WAT).
Liver and WAT are important for metabolic regulation.
As consequences of obesity, a fatty liver and adipocyte
hypertrophy play crucial roles in the development of
metabolic syndrome via multiple mechanisms including
impaired insulin signalling and inflammation [9,10]. To
better understand the influences of a western-style diet
that is high in fat and sucrose on the onset of obesity-
associated metabolic abnormalities, the present study
was designed to assess the short-term (2 and 4 weeks)
effects of a HF–HS diet on the risk factors for metabolic
disruptions. Therefore, we investigated the underlying
mechanism in C57BL/6 J mice, an inbred mouse strain
that has been used for studies of obesity and diabetes
owing to its susceptibility to these diseases in response
to a high-fat diet [11,12].
Methods
Animals
This study was approved by the Institutional Animal
Care and Use Committee at Kitayama Rabesu Inc.
(Nagano, Japan), where the animals were housed for the
entire experimental period. Eight-week-old male C57BL/
6 J mice (Charles River Laboratories, Inc., Kanagawa,
Japan) were housed in a room at 23 ± 1 °C with a 12/12-h
light–dark cycle.
Diets
The mice were fed two different diets. The low fat–low
sucrose diet was standard mouse chow CRF–1 (Oriental
Yeast Co. Ltd., Tokyo, Japan). Its composition was (wt/
wt): 5.4% fat, 53.8% carbohydrate, 21.9% protein, 2.9%
fibre, 6.6% minerals, added vitamins A, D, and E, and
0.02% cholesterol (357 kcal per 100 g). The HF–HS diet
was a milk fat–based diet (TD.88137; Harlan Laborator-
ies Inc., Indianapolis, IN, USA). Its composition was
(wt/wt): 21.2% fat, 49.1% carbohydrate (34.1% sucrose
plus 15% corn starch), 17.3% protein, 5.0% fibre, 3.5%
minerals, 0.4% CaCO3, 1% vitamin mix, 0.004% antioxi-
dants, and 0.2% cholesterol. Fats provided 42% of the
calories, and the diet yielded 450 kcal per 100 g.
Experimental protocol
The animals had free access to water and standard
mouse chow CRF–1 for an acclimatization period of
1 week. Thereafter, animals weighing 23–24 g were ran-
domly assigned to two groups for the feeding experi-
ment. The control group (n = 12) was fed standard
mouse chow CRF–1, and the HF–HS group (n = 12) wasfed the diet TD.88137, which was high in fat and su-
crose. Body weight and food intake were monitored
throughout the study. At the end of 2 weeks and 4 weeks,
the mice (the control group, n = 6; HF–HS diet group,
n = 6) were anesthetized with 4% sodium pentobarbital
(Dainippon Sumitomo Pharma, Osaka, Japan). Whole
blood was collected from the abdominal aorta into
EDTA-coated tubes, and plasma was obtained by centri-
fugation at 3000 rpm for 15 min at 4 °C and stored at
−80 °C until biochemical analysis. Liver and mesenteric
WAT were dissected and weighed after a short wash in
cold phosphate-buffered saline (pH 7.4). Organs were
immediately flash-frozen in liquid nitrogen and stored at
−80 °C until further lipid extraction and quantitative
polymerase chain reaction (QPCR) analysis. Liver por-
tions were fixed in 10% formalin for histological
examination.
Plasma biochemical analysis
Plasma triglycerides, free fatty acids, total cholesterol,
and high-density lipoprotein cholesterol (HDL–C) were
determined enzymatically using commercially available
reagent kits (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Low-density lipoprotein cholesterol
(LDL–C) was calculated as total cholesterol−HDL-
triglyceride × 0.2.
Plasma concentrations of insulin and adipokines,
which have wide-ranging effects on energy intake/
expenditure as well as on carbohydrate and lipid metabol-
ism, were measured by enzyme-linked immunosorbent
assays (ELISA). Mouse Insulin ELISA kit (Morinaga In-
stitute of Biological Science, Inc., Yokohama, Japan),
Mouse Adiponectin ELISA kit (Otsuka Pharmaceutical
Co., Ltd., Tokyo, Japan), and Mouse Resistin ELISA kit
(Shibayagi Co. Ltd., Gunma, Japan) were used to deter-
mine plasma levels of these proteins.
Extraction and analysis of hepatic lipid content
Extraction of total lipids from a portion of liver was
performed as described by Folch et al. [13] in the pres-
ence of butylated hydroxytoluene as an antioxidant.
Extracted lipids were dried using a vacuum concentra-
tor (Concentrator Plus 5305, Eppendorf ) and dissolved
in 2-propanol. Triglyceride and total cholesterol con-
centrations were determined using commercial enzyme
kits (Wako). For hepatic histology, formalin-fixed liver
tissue was embedded in paraffin, cut into 10-μm sec-
tions, and stained with hematoxylin and eosin. Oil Red
O (Sigma Aldrich, St. Louis, MO, USA) staining of neu-
tral lipids was done on frozen sections.
QPCR
Total RNA was extracted from frozen liver and WAT
using the SV Total RNA Isolation System (Promega
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turer’s instructions. RNA concentration and purity were
assessed based on absorbance at 260 nm and 280 nm.
First-strand cDNA was synthesized from total RNA
using a PrimeScript II 1st strand cDNA Synthesis kit
(TaKaRa Bio, Otsu, Japan) using oligo dT-adaptor pri-
mers and 1 μg total RNA as the template. The resulting
cDNA was used for QPCR amplification in a 96-well for-
mat with SYBR Premix Ex Taq (TaKaRa Bio) and a 7500
Real-Time PCR System (Life Technologies Co., Japan).
Expression levels of test genes were normalized to the
expression of the housekeeping gene encoding 18 S ribo-
somal RNA. The primers used for QPCR are listed in
Table 1.
Statistical analysis
The data are presented as the mean± SE. All statistical
tests were performed using the Student's t-test, and stat-
istical significance was considered as P< 0.05.
Results
Body, WAT, and liver weights
Mice in the HF–HS diet group gained weight rapidly.
As shown in Figure 1, the HF–HS diet increased the
body weight by 8.3% (P< 0.01), 9.1% (P< 0.05), 7.8%
(P< 0.01), and 11.4% (P< 0.01) at the end of weeks 1,Table 1 Primers used for QPCR

















AMPK: 5' adenosine monophosphate-activated protein kinase, Akt2: protein
kinase B beta, CD36: CD36 antigen, CD68: CD68 antigen, FAS: fatty acid
synthase, HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase, IRS2:
insulin receptor substrate 2, LDLR: low-density lipoprotein receptor, LPL:
lipoprotein lipase, LXRα: liver X receptor alpha, MAC1: macrophage-1 antigen,
MMP3: matrix metalloprotease 3, PPARγ: peroxisome proliferator activated
receptor gamma, SCD-1: stearoyl CoA desaturase-1, SREBP: sterol regulatory
element binding protein.2, 3, and 4, respectively, although food intake remained
unchanged in the two groups over the 4 weeks. Com-
pared with the control group fed standard chow diet,
mesenteric WAT weight in the HF–HS diet group
increased by 64.9% and 74.2% (P< 0.01 for both) at the
end of weeks 2 and 4, respectively. There were no differ-
ences in liver weight.
Plasma lipids profile
As shown in Figure 2, the HF–HS diet increased total
cholesterol by 103.8% (P< 0.001) and 97.1% (P< 0.01) at
the end of weeks 2 and 4, respectively. LDL–C was
increased by 218.6% and 175.5% (P< 0.001 for both) at
the end of weeks 2 and 4, respectively. HDL–C was
increased by 80.8% and 89.5% (P< 0.01 for both) at the
end of weeks 2 and 4, respectively. However, there were
no differences in the plasma triglyceride or free fatty
acid levels between the control and HF–HS groups.
Plasma levels of insulin and adipokines
As shown in Figure 3, the HF–HS diet caused 2.2-fold
and 1.1-fold increases (P< 0.01 for both) in plasma insu-
lin levels at the end of weeks 2 and 4, respectively, com-
pared to the control group. Concerning plasma
adipokine levels, there was an increase in plasma resistin
of 38% (P< 0.05) at the end of week 4 but not at week 2
in the HF–HS diet group compared to the control
group, whereas no difference in plasma adiponectin level
was found between the control and the HF–HS groups
at either time point.
Lipid accumulation in liver
Although the difference in hepatic cholesterol between
animals fed the control and HF–HS diets did not reach
statistical significance, the HF–HS diet elevated hepatic
triglyceride levels by 135% (P< 0.001) at week 2 and 42%
(P< 0.05) at week 4 (Figure 4A). Oil Red O staining of
liver tissue also showed that the HF–HS diet caused not-
able lipid accumulation as early as week 2 (Figure 4B).
Expression of key genes involved in lipid and cholesterol
metabolism and insulin signalling in liver
The expression of genes closely involved in lipogenesis
and lipid transport was rapidly upregulated in animals
given the HF–HS diet (Figure 5A). At week 2 and week
4, respectively, the HF–HS diet increased the mRNA
expression of liver X receptor alpha (LXRα) by 2.4 fold
(P< 0.01) and 1.1 fold (P< 0.05), that of sterol regula-
tory element binding protein 1c (SREBP-1c) by 2.7 fold
(P< 0.001) and 2.3 fold (P< 0.01), that of stearoyl CoA
desaturase-1 (SCD-1) by 4.4 and 4.6 fold (P< 0.001 for
both), that of fatty acid synthase (FAS) by 45% not sig-
nificant and 96% (P< 0.05), that of peroxisome prolif-


















































































Figure 1 Changes in body, white adipose tissue (WAT), and liver weights. Food intake and body weight (A) and mesenteric WAT and liver
weights (B) are shown. HF–HS diet: high fat–high sucrose diet. C57BL/6 J mice were fed standard chow diet or the HF–HS diet (milk fat 21% and






















































































































Figure 2 Effect of the HF–HS diet on the plasma lipid profile. Plasma levels of cholesterol (total cholesterol, LDL–cholesterol, and
HDL–cholesterol) (A), triglycerides (B), and free fatty acids (C) are shown. HF–HS diet: high fat–high sucrose diet. C57BL/6 J mice were fed
standard chow diet or the HF–HS diet (milk fat 21% and sucrose 34%) for 2 or 4 weeks. Values are the mean± SE, n = 6. ** P< 0.01; *** P< 0.001.










































































Figure 3 Effect of the HF–HS diet on plasma levels of insulin
and adipokines. Plasma levels of insulin (A), adiponectin (B), and
resistin (C) are shown. HF–HS diet: high fat–high sucrose diet.
C57BL/6 J mice were fed standard chow diet or the HF–HS diet
(milk fat 21% and sucrose 34%) for 2 or 4 weeks. * P< 0.05.
** P< 0.01.
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(not significant) and 4.5 fold (P< 0.05), and that of
lipoprotein lipase (LPL) by 2.7 fold and 1.2 fold (P
< 0.05 for both). In contrast, as shown in Figure 5B,
the HF–HS diet did not alter the expression of several
key genes involved in cholesterol biosynthesis, such as
sterol regulatory element binding protein 2 (SREBP-2),
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR),and low-density lipoprotein receptor (LDLR). Further-
more, mRNA expression from genes involved in insulin
signalling was downregulated by the HF–HS diet
(Figure 5C). At week 2 and week 4, respectively, the
HF–HS diet decreased the mRNA expression of insulin
receptor substrate 2 (IRS2) by 35% (not significant) and
68% (P< 0.01), that of protein kinase B beta (Akt2) by
58% (P< 0.05) and 71% (P< 0.01), and that of 5' adeno-
sine monophosphate-activated protein kinase (AMPK)
by 60% (P< 0.05) and 42% (P< 0.01).
Expression of genes related to lipid metabolism and
inflammation in WAT
As shown in Figure 6A, the HF–HS diet rapidly upregu-
lated the expression of genes involved in lipogenesis in
mesenteric WAT. At the respective weeks 2 and 4, the
HF–HS diet increased mRNA expression of SREBP1c by
3.3 fold and 1.4 fold (P< 0.05 for both), that of SCD-1
by 3.6 fold and 4.0 fold (P< 0.01 for both), and that of
FAS by 0.9 fold (not significant) and 0.5 fold (P< 0.05).
mRNA expression of the gene encoding the lipolytic en-
zyme LPL was increased by 3.2 fold (P< 0.05) and 6.7
fold (P< 0.001) by the HF–HS diet at weeks 2 and 4, re-
spectively. Furthermore, compared with the control
group, genes related to inflammation were upregulated
in animals given the HF–HS diet (Figure 6B). At the re-
spective weeks 2 and 4, the HF–HS diet increased the
mRNA expression of macrophage-1 antigen (MAC1) by
0.8 fold (not significant) and 2.9 fold (P< 0.01), that of
CD68 by 1.2 fold and 2.1 fold (P< 0.05 for both), and
that of matrix metalloprotease 3 (MMP3) by 2.2 fold
(P< 0.05) and 4.1 fold (P< 0.01).
Discussion
In this study, we demonstrated that short-term feeding
of the HF–HS diet caused gains in body and WAT
weight and hepatic steatosis as early as 2 weeks. The cal-
ories in the HF–HS diet were 26% higher than those in
the standard chow (control). Although there was no dif-
ference in food intake between animals given the control
and HF–HS diet, daily caloric intake was increased by
the HF–HS diet. Thus, rapid onset of visceral obesity
and fatty liver may occur with intake of a high-calorie
diet that is high in fat and sucrose.
Diet-induced obesity is largely caused by disorders of
fat metabolism, resulting in a massive accumulation of
fat in various tissues. Lipid and energy metabolism are
regulated by a complex network of signalling processes,
and we therefore investigated mRNA expression of key
genes regulating lipid metabolism such as LPL, SREBP1c,
SCD-1, FAS, LXRα, and PPARγ. The HF–HS diet upre-
gulated WAT and liver LPL mRNA expression. The lipo-
lytic enzyme LPL mediates uptake of circulating lipid
































































Figure 4 Effect of the HF–HS diet on hepatic lipid accumulation. (A) Hepatic triglyceride and total cholesterol levels. (B) Photomicrographs of
liver sections stained with hematoxylin-eosin and Oil Red O at week 2 (upper panel) and week 4 (lower panel). HF–HS diet: high fat–high sucrose
diet. C57BL/6 J mice were fed standard chow diet or the HF–HS diet (milk fat 21% and sucrose 34%) for 2 or 4 weeks. Values are the mean± SE,
n = 6. ** P< 0.01, *** P< 0.001.
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protein–triglyceride lipolysis [14]. Excessive circulating
lipids from the HF–HS diet may have stimulated LPL
overexpression, and it has been demonstrated that
tissue-specific overexpression of LPL in skeletal muscle
and liver increases cellular stores of triglycerides and
leads to insulin resistance [15]. mRNA levels of genes en-
coding lipogenic proteins such as SREBP1c, SCD-1, and
FAS were increased similarly by the HF–HS diet at weeks
2 and 4, suggesting a rapid effect of the HF–HS diet on
de novo lipogenesis. The lipogenic transcription factor
SREBP1c plays a crucial role in regulating fatty acid syn-
thesis, and SREBP1c–responsive major genes include
acetyl CoA carboxylase, FAS, which encodes a rate-
limiting enzyme in de novo fatty acid biosynthesis to pro-
duce palmitic acid, SCD-1, which converts stearic acid to
oleic acid, and glycerol-3-phosphate acyltransferase,which encodes the first committed enzyme in triglyceride
and phospholipid synthesis [16,17]. The HF–HS diet
contained 34% sucrose, and there is increasing evidence
that fructose and glucose, the components of sucrose,
contribute to the regulation of lipid metabolism partially
by acting as inducers of SREBP1c and SCD-1 [18,19].
Furthermore, LXR is also a potent stimulator of fatty acid
and triglyceride synthesis, and activation of LXRα in liver
is closely related to the development of non-alcoholic
fatty liver disease [20,21]. LXR binds to DNA as a hetero-
dimer with the retinoid X receptor (RXR) and acts as a
key transcriptional regulator of lipid metabolism,
mediated largely by LXR-dependent hepatic expression
of SREBP-1c and its downstream target genes [22,23].
LXR agonists induce the expression of genes associated
with fatty acid biosynthesis [24]. In the current study, a



















































































































































Figure 5 Effect of the HF–HS diet on hepatic genes for lipid/cholesterol metabolism and insulin signalling. (A) mRNA expression of genes
related to lipid metabolism: LXRa, SREBP1c, SCD-1, FAS, PPARγ, CD36, and LPL. (B) mRNA expression of genes related to cholesterol metabolism:
SREBP2, HMGCR, and LDLR. (C) mRNA expression of genes related to insulin signalling: IRS2, Akt2, and AMPK. HF–HS diet: high
fat–high sucrose diet. C57BL/6 J mice were fed standard chow diet or the HF–HS diet (milk fat 21% and sucrose 34%) for 2 or 4 weeks. Values are
the mean± SE and are relative to control values, which were set at 1.0. n = 6. * P< 0.05, ** P< 0.01, *** P< 0.001.
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shown that glucose binds to and stimulates the transcrip-
tional activity of LXR, and glucose induces expression of
LXR target genes with an efficacy similar to that of the
dietary LXR ligands, oxysterols, suggesting that glucose
is an endogenous LXR ligand [25]. In addition, hepatic
PPARγ has been reported to be closely related tohepatosteatosis, and several studies using diabetic or
obese murine models have shown that PPARγ expression
is elevated in liver [26-29]. Liver-specific disruption of
PPARγ in diabetic mice dramatically decreases hepatic
triglyceride levels and systemically perturbs insulin sig-
nalling [30]. Thus, a role for PPARγ as an inducer of stea-
























































































Figure 6 Effect of the HF–HS diet on WAT genes involved in lipogenesis and inflammation. (A) mRNA expression of genes related to
lipogenesis: SREBP1c, SCD-1, and FAS, and of the lipolysis-related gene, LPL. (B) mRNA expression of genes related to inflammation: MAC1, CD68,
and MMP3. HF–HS diet: high fat–high sucrose diet. C57BL/6 J mice were fed standard chow diet or the HF–HS diet (milk fat 21% and sucrose
34%) for 2 or 4 weeks. Values are the mean± SE and are relative to control values, which were set at 1.0. n = 6. * P< 0.05, ** P< 0.01,
*** P< 0.001.
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gene CD36 in liver by the HF–HS diet. Collectively, the
rapid response of lipid metabolism–related genes in
response to a diet high in fat and sucrose is likely
to contribute to the rapid effect of such a diet on obesity-
associated hepatosteatosis.
After feeding with the HF–HS diet, concomitant with
downregulation of IRS2, Akt2, and AMPK that are
involved in the insulin signalling pathway in liver, plasma
insulin levels were elevated similarly at weeks 2 and 4,
suggesting that impaired insulin signalling was rapidly
triggered in response to the HF–HS diet. Increased adi-
posity and hepatic lipid accumulation are closely asso-
ciated with insulin resistance [31]. The intracellular
accumulation of diglycerides leads to activation of pro-
tein kinase C, which in turn decreases insulin-stimulated
IRS-1/IRS-2 tyrosine phosphorylation, phosphoinositide-
3 kinase activation, and downstream insulin signalling
[32]. Chronic exposure to fructose causes hyperinsuli-
naemia and obesity through altered mechanisms that in-
clude the effect of fructose on ATP depletion and uric
acid generation [33], increased circulating C-peptide
levels that are often associated with insulin resistance
[34], involvement of the fructose transporter GLUT5
that shows significantly higher expression levels inyoung Zucker obese rats compared to lean controls [35],
and the hexosamine hypothesis, in which hexosamine
flux is thought to be involved in regulating glucose
pathways [36].
The HF–HS diet increased the expression of the
macrophage marker MAC1 as well as CD68 and the in-
flammatory marker MMP3 in WAT, and it significantly
elevated plasma resistin levels. Accumulating evidence
has shown that obesity-associated insulin resistance is
related to adipose tissue dysfunction that is aggravated
by the development of chronic mild inflammation
[37,38]. Infiltration of macrophages into the hypertrophic
adipose tissue promotes inflammation and introduces
pro-inflammatory adipokines into circulation and
insulin-targeted tissues [39]. Resistin, a pro-inflammatory
adipokine found in inflammatory zone 3 (Fizz3) and
adipocyte-specific secretory factor, has been shown to as-
sert its effects on the inflammatory pathway and impair
insulin sensitivity [40,41]. Circulating levels of resistin
are increased in obesity, and an increase in serum resistin
level has been shown to induce insulin resistance in
rodents, suggesting that hyperresistinaemia has a causal
relationship with obesity-associated insulin resistance
[42-44]. Therefore, the rapid elevated expression of
inflammation-related genes in WAT with the HF–HS
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levels, which in turn may contribute to impaired insulin
signalling and compensatory hyperinsulinaemia.
The HF–HS diet caused hypercholesterolaemia as
early as 2 weeks, but no difference was found in plasma
triglyceride and free fatty acid levels between the control
and HF–HS groups. A similar plasma lipid profile was
observed in mice fed a high-fat diet [45]. A wealth of
evidence has demonstrated the importance of SREBP2 in
regulating hepatic cholesterol homeostasis. SREBP2
upregulates key cholesterogenic genes, such as those en-
coding LDLR and HMGCR [46]. The HF–HS diet did not
alter the mRNA expression of these genes that play cru-
cial roles in regulating cholesterol synthesis, suggesting a
minor role for cholesterogenic genes in the hypercholes-
terolaemia induced by the HF–HS diet. Furthermore, the
absence of changes in plasma lipid levels with the HF–
HS diet may possibly be explained by elevated plasma
triglyceride clearance that is partially due to increased
expression of LPL and CD36 in liver. In addition to LPL,
CD36 also influences the uptake of circulating fatty
acids. CD36 is an 88-kDa glycoprotein located at the
plasma membrane that plays a key role in enhancing
fatty acid uptake into cells. CD36 overexpression in
human hepatoma cells increases the uptake of fatty
acids, whereas a CD36 deficiency significantly impairs
fatty acid uptake by peripheral organs such as heart,
skeletal muscle, and adipose tissue in rodents [47,48].Conclusions
In conclusion, the present study demonstrated that in-
gestion of a diet high in fat and sucrose by mice signifi-
cantly elevated WAT weights, hepatic steatosis, and
plasma insulin levels as early as 2 weeks. Expression of
genes involved in the multiple steps of lipid accumulation
and inflammation in liver and WAT increased rapidly in
response to the HF–HS diet, and expression of these
gene products may have contributed to the rapid accu-
mulation of lipids in these organs and may have further
impaired hepatic insulin signalling, leading to compensa-
tory hyperinsulinaemia.
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